Loading...
•
Dec 31, 2019
Ardelyx Q4 2019 Earnings Report
Ardelyx reported financial results for the fourth quarter and full year ended December 31, 2019, and highlighted key accomplishments, including progress in the development of tenapanor and FDA approval for IBSRELA®.
Key Takeaways
Ardelyx reported total revenues of $2.25 million for the fourth quarter of 2019 and a net loss of $19.79 million. The company's cash, cash equivalents, and short-term investments are expected to fund operations until early 2022.
On track to submit NDA for Tenapanor for the control of serum phosphorus in mid-2020.
Total revenues were $5.3 million for the year ended December 31, 2019 related to the company’s ex-U.S. collaboration partnerships
Received FDA approval for IBSRELA® (tenapanor).
Raised approximately $135 million, net of underwriting discounts and commissions, following a successful underwritten public offering of 23,000,000 shares of common stock
Revenue by Segment
Forward Guidance
Ardelyx maintains its expectation that its cash, cash equivalents and short-term investments will be sufficient to fund the company’s operations until early 2022 based on its current operating plans.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...